A band that transmits electrical signals and stops migraine pain has been approved by the European Commission for pharmaceuticals.
Relivion, patented by Netanya-based Neurolief, is a brain neuromodulation device geared toward helping individuals who suffer from a range of neurological and neuropsychiatric disorders, including migraine headaches.
It is the first device of its kind considered safe for outpatient use.
Migraines can cause moderate to severe pain, including throbbing or pulsing. Often, the pain occurs only on one side of the head. Side effects can be nausea, weakness or sensitivity to light and sound.
According to the Migraine Research Foundation, migraines are the third most prevalent illness in the world. Nearly one in four United States households have someone who suffers from these headaches. The foundation said around 12% of the American population – including children – suffers from migraines. They are more common in women than men.
In Israel, the prevalence of migraines among those aged 21 and over is 5.4%, affecting 3.2% of men and 7.5% of women, according to Hadassah Medical Center.
